News

Vascazen is used to treat patients with Omega-3 fatty acids deficiency. Pivotal Therapeutics president Rachelle MacSweeney said the launch of Vascazen in North America is a key milestone

As per the agreement, Altacor will undertake research and development on Proximagen’s 5HT2c programme drug candidate – PRX00933 – in treating glaucoma. The company claims, PRX00933 which is

As per the agreement, UCB has acquired Lectus drug discovery and development programmes targeting ion channels used to treat specific set of Central Nervous System (CNS) indications. UCB

The double-blind, placebo-controlled trial, enrolling 60 US subjects, is designed to assess the pharmacokinetic, pharmacodynamic and safety profile of single escalating doses of CR845 in enteric-coated capsules. Cara

The acquisition is expected to help Tjoapack in its growth strategy. Tjoapack specializes in packaging medicines in a solid dosage form and is known for mass serialisation. By

The financial details of the contract have not been disclosed. OctoPlus provides formulation development and clinical material manufacturing services, besides offering drug delivery technologies to develop controlled release

The system is marketed to companies developing biopharmaceuticals including novel compounds and biosimilars with an emphasis on therapeutic monoclonal antibodies. BioFactura president and CEO Darryl Sampey said the

The double blind, placebo controlled trial will enroll 40 patients with prodromal or mild Alzheimer’s disease to measure physical changes in the brains of patients treated with PBT2

EXC 001 drug, co-developed by Excaliard and Isis Pharmaceuticals, is an antisense oligonucleotide that will hinder the process of fibrosis. As per the deal, Pfizer will provide Excaliard